Nature Communications (Aug 2024)

Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation

  • Si-Jia Sun,
  • Xiao-Dong Jiao,
  • Zhi-Gang Chen,
  • Qi Cao,
  • Jia-Hui Zhu,
  • Qi-Rui Shen,
  • Yi Liu,
  • Zhen Zhang,
  • Fang-Fang Xu,
  • Yu Shi,
  • Jie Tong,
  • Shen-Xi Ouyang,
  • Jiang-Tao Fu,
  • Yi Zhao,
  • Jun Ren,
  • Dong-Jie Li,
  • Fu-Ming Shen,
  • Pei Wang

DOI
https://doi.org/10.1038/s41467-024-50996-5
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 23

Abstract

Read online

Abstract Immune checkpoint inhibitor (ICI)-induced myocarditis involves intensive immune/inflammation activation; however, its molecular basis is unclear. Here, we show that gasdermin-E (GSDME), a gasdermin family member, drives ICI-induced myocarditis. Pyroptosis mediated by GSDME, but not the canonical GSDMD, is activated in myocardial tissue of mice and cancer patients with ICI-induced myocarditis. Deficiency of GSDME in male mice alleviates ICI-induced cardiac infiltration of T cells, macrophages, and monocytes, as well as mitochondrial damage and inflammation. Restoration of GSDME expression specifically in cardiomyocytes, rather than myeloid cells, in GSDME-deficient mice reproduces ICI-induced myocarditis. Mechanistically, quantitative proteomics reveal that GSDME-dependent pyroptosis promotes cell death and mitochondrial DNA release, which in turn activates cGAS-STING signaling, triggering a robust interferon response and myocardial immune/inflammation activation. Pharmacological blockade of GSDME attenuates ICI-induced myocarditis and improves long-term survival in mice. Our findings may advance the understanding of ICI-induced myocarditis and suggest that targeting the GSDME-cGAS-STING-interferon axis may help prevent and manage ICI-associated myocarditis.